FAQ

GC33

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
0120082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
GPC-3 in hepatocellular carcinoma: current perspectives
Glypican-3 (GPC3), a member of heparan sulfate proteoglycans, attaches to the cell membrane and is frequently observed to be… (More)
  • figure 1
Is this relevant?
2014
2014
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2014
Review
2014
Glypican-3 antibodies: a new therapeutic target for liver cancer.
Glypican-3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though the biological function of… (More)
Is this relevant?
2013
2013
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
PURPOSE GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 1
Is this relevant?
2011
2011
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
4085 Background: Glypican 3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically… (More)
Is this relevant?
2011
2011
Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
BACKGROUND GC33 is a recently developed monoclonal antibody against human glypican-3 (GPC3), which is significantly upregulated… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2010
2010
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Glypican 3 (GPC3), a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, is expressed in a majority of… (More)
Is this relevant?
2009
2009
Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
Previously, we demonstrated the antitumor efficacy of the anti-glypican-3 (GPC3) antibody GC33 in several human liver cancer… (More)
Is this relevant?
2009
2009
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Glypican 3 (GPC3), a GPI-anchored heparan sulfate proteoglycan, is expressed in the majority of hepatocellular carcinoma (HCC… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2008
2008
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?